Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Authors
Keywords
-
Journal
Lancet HIV
Volume 8, Issue 11, Pages e679-e689
Publisher
Elsevier BV
Online
2021-10-13
DOI
10.1016/s2352-3018(21)00185-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine
- (2021) Amy G. Cutrell et al. AIDS
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
- (2020) Chloe Orkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
- (2020) Susan Swindells et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabotegravir Plus Rilpivirine: First Approval
- (2020) A. Markham DRUGS
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- (2020) Michael S. Saag et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2020) Edgar T Overton et al. LANCET
- Adherence to HIV treatment regimens: systematic literature review and meta-analysis
- (2019) Frederick Altice et al. Patient Preference and Adherence
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment
- (2019) Dionne M. Hines et al. Patient Preference and Adherence
- HIV treatment and prevention 2019
- (2019) Nittaya Phanuphak et al. Current Opinion in HIV and AIDS
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
- (2017) David A Margolis et al. LANCET
- The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009–11
- (2016) Catherine R Lesko et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a series of meta-analyses
- (2016) Sergio Rueda et al. BMJ Open
- A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy
- (2014) Kasey R. Claborn et al. Psychology Health & Medicine
- The end of AIDS: HIV infection as a chronic disease
- (2013) Steven G Deeks et al. LANCET
- The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals
- (2009) AIDS
- European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults
- (2008) N Clumeck et al. HIV MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now